AstraZeneca to open new $300 million manufacturing facility in Maryland

Feb. 7, 2024
The plant will focus on the manufacturing of CAR-T cell therapies to enable cancer clinical trials.

AstraZeneca has announced plans to open a new manufacturing facility in Rockville, Maryland. The biopharmaceutical company will invest $300 million into the project, generating 150 new jobs in the process. Operations at the new 84,000 square-foot facility are expected to begin in 2026. According to the company, the plant will focus on the manufacturing of CAR-T cell therapies to enable cancer clinical trials. The Maryland Department of Commerce is in the process of approving a $500,000 conditional loan through the Advantage Maryland program, while Montgomery County’s Economic Development Fund will contribute an additional $100,000 conditional grant.